Background: Intratumoral steroidogenesis and its potential relevance in castration-
VCaP, DuCaP, LNCaP, and their respective CRPC sublines. The antiandrogen RD162, but not CYP17A1 inhibition with TAK700, abiraterone or siRNA, was able to block Preg-and Prog-induced proliferation. In contrast to TAK700, abiraterone also affected dihydrotestosterone-induced cell growth, indicating direct AR binding.
Furthermore, Prog-induced AR translocation was not affected by treatment with TAK700 or abiraterone, while it was effectively blocked by the AR antagonist enzalutamide, further demonstrating the direct AR activation by Prog.
Conclusion: Activation of the AR by clinically relevant levels of Preg and Prog accumulating in abiraterone-treated patients may act as a driver for CRPC. These data provide a scientific rationale for combining CYP17A1 inhibitors with antiandrogens, particularly in patients with overexpressed or mutated-AR. by combining abiraterone acetate with androgen deprivation therapy (ADT) vs ADT alone in metastatic hormone-sensitive prostate cancer. 5, 6 In contrast, the selective 17,20-lyase inhibitor TAK700 (Orteronel]) 7 failed to demonstrate a survival benefit in either the pre-or postdocetaxel setting. 8, 9 With novel hormonal agents now becoming the mainstay of advanced prostate cancer (PC) therapy in both hormone-naïve and castration-resistant setting, it is of importance to identify resistance mechanisms to these agents.
Clinical data have shown that a subgroup of patients with CRPC progressing on abiraterone still responds to enzalutamide, 10 suggesting that the AR signaling axis is still active in these patients despite low circulating androgen levels. 11 Several hypotheses have been postulated on the origin of AR reactivation in CRPC and CYP17A1-inhibitor resistant disease. Indeed, Chen et al 12 found the T877A AR mutation, rendering the AR activatible to progestagens, in 3 of 18 clinical abiraterone-resistant CRPC samples. Romanel et al 13 showed
that not only AR gene modifications but also wild-type AR copy number gain were associated with poor response to abiraterone and impaired overall survival. In addition, expression of the ligandindependent AR variant V7 has been associated with a poor response to both enzalutamide and abiraterone. 
| Cell proliferation assays
For cell proliferation assays, 5,000 cells per well were plated in 96-well dishes in their respective medium with DCC. After overnight attachment, the synthetic androgen R1881, steroids, and compounds were added to reach the indicated concentrations in a final volume of 200 μL. After 9 days, cell proliferation was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-assay as described previously. 30 
| Steroids and compounds
For cell culture assays, RD162, a nonsteroidal antiandrogen was used (Merck, Oss, Netherlands). It is closely related to and was selected from the same drug-screen as MDV3100 (enzalutamide). In vitro and in vivo, it has equal potency in AR-antagonism as enzalutamide and no significant difference in bioavailability in preclinical testing. 31 For AR binding assays, enzalutamide (Axon Medchem, Groningen, The Netherlands) was used because of its current use in clinical practice. Table S1 ). ).
| Δ4-Androstenedione analysis

| CYP17A1 knockdown
After overnight attachment, cells were transfected with CYP17A1 or nontargeting small interfering RNA (siRNA; On-TARGETplus SMARTpool siRNA; Dharmacon, Lafayette, LA) using Lipofectamine RNAiMax (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Twenty-four hours after transfection, the medium was replaced by DCC medium with indicated steroids. RNA was isolated after 48 hours or proliferation determined at day 6.
| Gene expression analysis
For quantitative polymerase chain reaction (qPCR) studies, RNA was isolated using RNA-Bee (TEL-TEST Inc, Friendswood, TX) from cultures treated for 48 hours with indicated compounds/steroids, 24 hours after seeding in DCC medium at 100.000 cells per well.
Reverse transcriptase and qPCR runs were performed as described Table S2 . Gene expression was calculated as fold expression over housekeeping genes GAPDH or PBGD and vehicle treated cells.
| Nuclear AR import studies
Nuclear translocation of the AR has been studied in time as well as in end-point measurements using fluorescence confocal microscopy on MOLL ET AL.
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PC346C cells stably expressing enhanced green fluorescent protein (EGFP)-AR. 29 To measure the effect of a concentration range of Preg and Prog, cells were seeded in a glass bottom 96-well plate in culture medium supplemented with the charcoal-stripped serum to avoid premature AR activation. Sixteen hours before imaging enzalutamide, TAK700, abiraterone (1 μM), and DMSO carrier only as control were added. Subsequently, 4 hours before imaging potential AR translocation was initiated using 0, 1, 10, and 100 nM Preg or Prog, and with 0.1 and 1 nM R1881 as the positive control, and nuclei were stained with Hoechst for reference. Cells were imaged using the Opera Phenix HCS system equipped with an x40 water immersion objective.
Hoechst and EGFP were exited using 405 and 488 nm lasers and were visualized using 435 to 480 nm and 500 to 550 nm band-pass filters. EGFP intensities were measured in the nuclear (nuc) and the peri-nuclear (cyto) regions. Nuclear translocation of the AR was expressed by nuclear signal intensity/(nuclear signal intensity+cyto-plasmatic signal intensity), after background subtraction.
The ratio of AR nuclear localization was expressed as:
For the analysis of AR-translocation dynamics, cells were seeded on glass coverslips in six-well plates. After overnight attachment, cells were treated with TAK700 (3 µM) or vehicle for 12 hours and subsequently transferred to a live-cell chamber and maintained at 37°C and 5% CO 2 .
Time-lapse imaging was performed using a Zeiss LSM510 confocal microscope (Carl Zeiss, Jena, Germany), equipped with a 63 × 1.3 NA oil Figure S4 ). Of note, CYP17A1 messenger RNA (mRNA) could not be detected in LNCaP nor in PC346C (Table   S3 ). Also, we were unable to detect CYP17A1 protein in VCaP despite detectable mRNA levels. (Figure S5 ). The AR-driven effects in the presence of TAK700 indicate that growth of these CRPC clones, despite upregulated CYP17A1 mRNA, was not dependent on the increased activity of de novo steroidogenesis.
Prog and Preg stimulate cell growth of castration-naïve VCaP and DuCaP cells via AR activation to test if Preg and Prog could also
facilitate cell growth of castration-naïve parental VCaP and DuCaP, characterized by relatively low levels of CYP17A1 (Table S3) To further substantiate that cell growth in hormone-naive PC cells is independent of CYP17A1, VCaP, and DuCaP were treated with siRNA for CYP17A1. Similarly to incubation with TAK700, treatment with CYP17A1 siRNA-resulting in undetectable levels of CYP17A1 mRNAdid not affect Prog stimulated levels of PSA mRNA in parental VCaP ( Figure 3C ). Likewise, in DuCaP, Preg-and Prog-induced cell proliferation was unaffected by CYP17A1-directed siRNA ( Figure 3D ). The number in the top-left of each picture indicates average nuclear/total AR signal ratio. Corresponding graph bars with SD are provided in Figure S7 . AR, androgen receptor; CYP17A1, cytochrome P450, family 17, subfamily A, polypeptide 1; DMSO, dimethyl sulfoxide; GFP, green fluorescent protein; Preg, pregnenolone; Prog, progesterone F I G U R E 3 Preg-and Prog-induced cell growth of castration-naïve VCaP and DuCaP is independent of CYP17A1 activity. Cells were treated with 100 nM of Preg (light gray) or Prog (dark gray), or 0.1 nM DHT (black) with or without TAK700 (A) or abiraterone (B) at indicated concentrations. Data shown are mean ± SE of three independent experiments. C, VCaP cells were transfected with 2.5 or 5 nM CYP17A1-directed or 5 nM scrambled siRNA (Dharmacon) for 24 hours, after which cells were incubated with vehicle or 100 nM Prog for 48 hours after which CYP17A1 and PSA mRNA expression were assessed by qPCR with each sample in duplicate. D, DuCaP cells were transfected with 2.5 or 5 nM CYP17A1 siRNA or 5 nM scrambled siRNA (Dharmacon) for 24 hours and subsequently incubated with Preg, Prog, or vehicle (ethanol) for 6 days. Cell proliferation was assessed by MTT assay. Data shown are mean ± SE of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001. AR, androgen receptor; CYP17A1, cytochrome P450, family 17, subfamily A, polypeptide 1; DCC, dextran-coated charcoal-stripped fetal calf serum; DHT, dihydrotestosterone; mRNA, messenger RNA; Preg, pregnenolone; Prog, progesterone; qPCR, quantitative polymerase chain reaction; siRNA, small interfering RNA resistance to these agents. 13, 32 Data on precursor steroid levels in patients treated with abiraterone are scarce. As a surrogate measure of systemic steroid concentrations, urinary Preg and Prog metabolites in patients treated with abiraterone without exogenous glucocorticoids have previously been shown reported to be 2.5 to 44 and 3.8 to 61 times higher compared with baseline. 25 In patients treated with concomitant glucocorticoids, serum levels of Preg and Prog decreased markedly (Table S1 ). Taplin Abiraterone and TAK700 effectively inhibit steroid synthesis, but cannot prevent direct binding of the steroid precursors Preg or Prog to the AR (dotted line). Direct AR-antagonism by enzalutamide will still block activation by either DHT or Prog. AR, androgen receptor; CRPC, castration-resistant prostate cancer; CYP17A1, cytochrome P450, family 17, subfamily A, polypeptide 1; DHT, dihydrotestosterone; Preg, pregnenolone; Prog, progesterone underscore reports that intratumoral de novo steroidogenesis is not essential for CRPC growth. 36 We demonstrate that inhibition of AR-mediated cell growth by abiraterone can be (partly) explained by direct AR-antagonism, albeit at peak concentrations. This is consistent with data that abiraterone can bind to and antagonize AR in LNCaP and VCaP, 37, 38 and our prior report that abiraterone can also partially block AR nuclear translocation. 29 Furthermore, the previously observed 3βHSD inhibition, 39 combined with the antiandrogenic potency and inhibition of CYP17A1, 3βHSD, and SRD5A by the abiraterone metabolite, D4-abiraterone, 40 may explain the beneficial effect of abiraterone in clinical trials relative to TAK700, which seems to lack these additional effects.
To date, two retrospective studies reported PSA response rates of 27% and 30% for enzalutamide in abiraterone progressive patients. 41, 42 Interestingly, in a third retrospective study, PSA responses for enzalutamide after abiraterone vs abiraterone after enzalutamide have been reported to be higher (30% vs 6%), with a trend towards longer PFS in the first group. 43 In contrast, adding abiraterone to continued enzalutamide treatment did not result in a significant delay of PSA progression vs abiraterone alone in patients with biochemical progression on enzalutamide. 44 However, none of these studies have interrogated the upfront combination of ARantagonism with androgen synthesis inhibition.
Although our study may be limited by the use of in vitro models, it is important to note that these different cell lines were selected 
